As the accumulation of deleterious mutations should adversely impact the fitness of a tumour (67), we were intrigued why an increased mutation rate is apparently selected for in prostate cancer via hypermethylation of GSTP1 and GSTM2. Here, GSTM2 is linked to prostate cancer.